RecruitingAcute Respiratory Distress Syndrome (ARDS)ARDSARDS (Acute Respiratory Distress Syndrome)

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

Eligible age

18+ yrs

Accepts

All genders

Locations

23 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Cohort B: Participants will be randomized to receive either a placebo or paridiprubart. This record describes the default procedures and analyses for Cohort B. Please see NCT06703073 for information on the BP-ARDS-P2-001 Master Protocol.

Sponsor: PPD Development, LP

You may qualify if…

✓ The following inclusion criteria are in addition to the exclusion criteria specified in the Master Protocol NCT06703073:
✓ ARDS Severity of moderate or severe based on PaO2/FiO2 or SpO2/FiO2 assessment at the time of randomization.

You may not qualify if…

✕ The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol NCT06703073.
✕ Participant has a known allergy or known hypersensitivity to paridiprubart or its excipients, including polysorbate 80
✕ Participant with established cirrhosis and a modified Child-Pugh Score of 12 or greater